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Background: Increased vitamin B6 catabolism related to inflammation, as measured 
by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and 
pyridoxal -5'-phosphate), has been positively associated with lung cancer risk in two 
prospective European studies. However, the extent to which this association translates 
to more diverse populations is not known. 
Materials and methods: For this study, we included 5,323 incident lung cancer cases 
and 5,323 controls individually matched by age, sex, and smoking status within each 
of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific 
odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr 
and lung cancer risk were calculated using conditional logistic regression and pooled 
using random-effects models.  
Results: PAr was positively associated with lung cancer risk in a dose-response 
fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 
(95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and 
lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-
2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years 
of blood draw (OR: 1.73, 95% CI: 1.34-2.23). 
Conclusion: Based on pre-diagnostic data from 20 cohorts across 4 continents, this 
study confirms that increased vitamin B6 catabolism related to inflammation and 
immune activation is associated with a higher risk of developing lung cancer. 
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Lung cancer remains the leading cause of cancer death in the US [1] and worldwide 
[2], with less than one out of five cases surviving more than 5 years following 
diagnosis [3]. In addition to smoking, the primary risk factor for lung cancer, chronic 
inflammation is believed to play a critical role in cancer development [4], and may be 
involved in the tumor-promoting effect of smoking [4]. A recent randomized trial 
revealed a potential protective effect of anti-inflammatory therapy on lung cancer 
incidence and mortality [5]. 
 
Circulating pyridoxal-5'-phosphate (PLP), the widely used marker of vitamin B6 
status, has been linked to risk of various cancers in epidemiological studies, including 
lung cancer [6]. However, the estimated associations of PLP with lung cancer risk 
vary considerably across studies [7-9], which may be due to the fact that circulating 
concentrations of PLP are influenced by several factors, including dietary or 
supplemental intake, inflammation, serum albumin and alkaline phosphatase levels 
[10].  
 
Considering the limitations of PLP as a biomarker, we have proposed the PAr index, 
defined as the ratio 4-pyridoxic acid (PA) / (pyridoxal + PLP) [11, 12]. Several 
inflammation-related processes involving PLP-catabolizing enzymes, oxidative stress 
and kidney damage may contribute to a skewing of the concentrations of B6 vitamers 
in plasma toward more PA relative to pyridoxal+ PLP, resulting in an elevated PAr 
[13]. Therefore, PAr serves as a marker of increased vitamin B6 catabolism during 




findings from two studies, the Hordaland Health Study (HUSK) [14] and the 
European Prospective Investigation into Cancer and Nutrition (EPIC) [13], suggesting 
that PAr is associated with lung cancer risk. For instance, the EPIC study that 
included 892 cases and 1748 matched controls suggested that a doubling in PAr levels 
was associated with 52% higher lung cancer risk, and the risk increased most in 
former smokers and for squamous cell carcinoma (SCC) [13]. 
 
However, current evidence on PAr and lung cancer has been limited to European 
populations. Circulating levels of vitamins and their metabolites vary substantially 
across cohorts and continents due to many factors, including diet, lifestyle, vitamin 
supplementation and food fortification [15]. Considering the large variations in PLP 
and PAr levels [15], it is not known if the reported positive association of PAr with 
lung cancer applies to populations with wide variance in the levels of this biomarker. 
 
In order to comprehensively evaluate this question, we conducted a study of PAr 
within the Lung Cancer Cohort Consortium (LC3), the largest investigation to date 
assessing biomarkers of one-carbon metabolism in lung cancer, involving 20 










Study population and design 
 
Details of the LC3 have been reported previously [8]. In brief, a total of 20 
prospective cohort studies, which were members of the US National Cancer Institute 
(NCI) Cohort Consortium in 2009 and had cryopreserved plasma/serum samples 
available were included. The LC3 included 11 cohorts from the United States, 4 
cohorts from Europe (Norway, Sweden, and Finland), 4 cohorts from Asia (China and 
Singapore), and 1 cohort from Australia, resulting in a combined cohort population of 
more than 2,000,000 participants [8]. Written informed consent was provided by all 
study participants, and the research was approved by the institutional review board of 
the International Agency for Research of Cancer and each participating cohort. 
 
Cases ascertainment and control selection 
 
Lung cancer cases were defined on the basis of the International Classification of 
Diseases for Oncology, Second Edition (ICD-O-2) and included invasive cancers 
coded as C34.0-C34.9. From the 11,399 incident lung cancer cases with pre-
diagnostic blood samples, 5,545 cases were selected. Never and former smokers were 
oversampled to increase statistical power in analyses stratified by smoking. For each 
case, one control was selected by incidence density sampling and matched by cohort, 
sex, race (US cohorts only), date of birth (± 1 year, relaxed to ± 3 years), date of blood 
collection (± 1 month, relaxed to ± 3 months), and smoking status in 5 categories: 




years since quitting), and light and heavy smokers among current smokers (< 15, ≥15 
cigarettes per day). After various exclusions [8], 5,364 lung cancer case-control pairs 
were included. We further excluded 41 case-control pairs with missing PA, pyridoxal 





All blood samples were stored at ≤−80°C until shipment to the Bevital laboratory 
(www.bevital.no) for biochemical analyses. The time from blood draw to the 
measurement of PA, pyridoxal and PLP ranged from 2 to 38 years. Concentrations of 
PA, pyridoxal, PLP, cotinine (a marker of recent nicotine exposure) [16] and 
creatinine [17] were determined by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). Cases and their matched controls were analyzed together within the 
same batches in random order, with laboratory staff blinded to the case-control status 
of the blood samples. The within-day coefficients of variation (CVs) for the assays 
were 2.3-4.6% and between-day CVs were 2.2-12.3% [15, 16]. The estimated 
glomerular filtration rate (eGFR) was calculated on the basis of the chronic kidney 




Geometric mean (95% CI) of PAr in each cohort was estimated by using generalized 




and eGFR (continuous). The correlation between PAr and eGFR was assessed using 
Spearman’s correlation coefficient, adjusted for age, sex and cohort. 
 
We used a two-stage modelling approach [19] to estimate the association between PAr 
and lung cancer risk. In the first stage, conditional logistic regression models were 
used to calculate cohort-specific odds ratios (ORs) with 95% confidence intervals 
(CIs) for lung cancer, conditioning on individual case sets. ORs were calculated for 
the fourth relative to the first quartile of PAr based on its distribution among the 
control subjects within each cohort, due to large differences in PAr levels across 
cohorts. The models were adjusted for pre-defined covariates including eGFR 
(continuous) and cotinine concentrations as quartiles defined from the distribution 
among current smokers. In sensitivity analysis, the models were additionally adjusted 
for body mass index (continuous). Also, we fitted models that were additionally 
adjusted for smoking duration or pack-years of smoking among ever smokers. In the 
second stage, study-specific ORs were pooled using random-effects meta-analysis, 
taking the possibility of between-study heterogeneity into account. Heterogeneity 
across subgroups was assessed by Cochrane’s Q test and the I2 index [20]. 
 
The primary analyses were conducted using all the study participants, and by region. 
We additionally generated risk estimates within strata by sex and smoking (never, 
former and current smokers) using the same approach. Stratified risk analyses were 
also conducted by histology of lung cancer and by years from blood draw to 
diagnosis. Our secondary analysis included PAr as a continuous exposure, using log2-
transformed PAr in conditional logistic regression models. Estimates from this model 





All statistical analyses were performed using SAS (Version 9.4; SAS Institute, Inc., 
Cary, NC). Figures were produced using R (version 3.4.2, www.r-project.org). All 












Descriptive analyses  
 
Characteristics of the 10,646 study participants at baseline are shown in Table 1. Of 
the individually matched cases and controls, 54% were men. Overall, the median age 
at blood draw was 62 years, and the median time from blood draw to diagnosis of 
lung cancer was 6.1 years. Nearly half of the participants (47%) were current 
smokers, 28% were former smokers, and 25% never smokers. In addition, the PAr 
level (median (5th-95th percentile)) among never, former and current smokers was 0.36 
(0.16-0.93), 0.50 (0.22-1.22) and 0.41 (0.14-0.96), respectively. PAr levels varied 
substantially across cohorts (Figure 1) and regions (Table 1). The adjusted geometric 
mean of PAr was highest (0.51) in the US cohorts and lowest (0.29) in the Asian 
cohorts. We observed an inverse relation between PAr and eGFR (Spearman's rho = -
0.19, p<0.001). 
 
Overall analysis of the association between PAr and lung cancer risk  
 
PAr was positively associated with lung cancer risk in a dose response fashion (Figure 
2), with OR (95% CI) in the highest versus lowest quartile of 1.38 (1.19-1.59). When 
analyzing PAr as a continuous log2-transformed variable, a doubling in PAr was 
associated with 1.14-fold risk of lung cancer (OR for log2 PAr: 1.14, 95% CI: 1.05-
1.25) (overall Pheterogeneity = 0.006; I
2= 49.2%) (Supplemental Figure 1). The strongest 
risk association was observed in Europe (OR: 1.67, 95% CI: 1.24-2.26), followed by 




observed in Asia or Australia (overall Pheterogeneity = 0.14; I
2= 27.9%) (Figure 3). The 
weakest associations were generally found in cohorts that only included women 
(Supplemental Figure 1). Further adjustment for body mass index rendered the overall 
OR estimates slightly stronger (data not shown). 
 
Stratified analysis by sex and smoking 
 
As shown in Figure 4, the association between PAr and lung cancer appeared stronger 
in men than in women (Pheterogeneity = 0.07; I
2= 69.5%), with a 60% increased risk when 
comparing the fourth vs. first quartile in men. This association was mainly driven by 
men from the European and US cohorts.  Effect modification was also present for 
smoking categories (Pheterogeneity = 0.006; I
2= 79.6%), with the strongest association 
observed among former smokers (pooled OR: 1.69, 95% CI: 1.36-2.10 for the fourth 
vs. first quartile of PAr) (Supplemental Figure 2). After further adjustment by number 
of years of smoking or pack-years of smoking, the risk estimates did not change 
essentially among former smokers but were somewhat attenuated among current 
smokers (Supplemental Table 1). 
 
Stratified analysis by histology and time to diagnosis 
 
Stratified analysis by histology showed that the risk association of PAr appeared 
strongest for SCC (adjusted OR: 1.30, 95% CI: 0.95-1.78 for the fourth vs. first 
quartile of PAr), followed by adenocarcinoma (adjusted OR: 1.26, 95% CI: 1.04-
1.52), small cell carcinoma (adjusted OR: 1.22, 95% CI: 0.84-1.78), and large cell 




estimates were strongest for those who received their lung cancer diagnosis within 3 
years of blood draw (adjusted OR: 1.73, 95% CI: 1.34-2.23), and gradually decreased 
by increasing time from blood draw to lung cancer diagnosis (Supplemental Figure 3). 
In order to address an effect of potentially established cancer on PAr at baseline, we 
excluded 411 cases diagnosed within the first year after blood draw and their matched 
controls from the analysis, and observed consistent results. The risk estimates 
remained strongest for those who received their lung cancer diagnosis 1-3 years after 







Principal findings  
 
In this study of pre-diagnostic individual level data from 20 nested case-control 
studies across Asia, Australia, Europe and the USA, we observed that study 
participants with increased vitamin B6 catabolism, as indicated by elevated PAr index, 
had an increased risk of developing lung cancer. This association was strongest in 
men, former smokers, and those who received a lung cancer diagnosis within the first 
3 years after blood draw. 
 
Comparison with previous studies 
 
This study confirms our previously reported findings [13, 14] that PAr is positively 
associated with lung cancer risk, in particular among men who had ever smoked. 
Stratified analysis from the present large study showed that the risk association 
appeared to be strongest in men, former smokers and participants diagnosed with 
SCC, which is in agreement with results from the EPIC study including 8 European 
countries [13]. Of note, the European cohorts in the LC3 generated a stronger risk 
estimate (OR: 1.31, 95% CI: 1.10-1.57 for log2 PAr) than cohorts from Asia, Australia 
or USA. However, the estimate was still lower than that in EPIC (OR: 1.52, 95% CI: 
1.27-1.81 for log2 PAr), which is presumably attributable to differences in cohort 
recruitment and characteristics including levels of PLP and PAr. The European 
cohorts in the LC3 were exclusively from Finland, Norway and Sweden, and had 




additionally included cohorts from Central and Southern European regions, which had 
relatively higher plasma PLP and lower PAr levels compared to the Nordic countries.  
 
Our findings in LC3 showed that the association between PAr and lung cancer risk 
was stronger for those who received their lung cancer diagnosis within the first 3 
years after blood draw, which is also similar to previously reported findings for PLP 
[8] and functional vitamin B6 status [21] in LC3. This particular observation suggests 
preclinical metabolic changes, i.e. increased vitamin B6 catabolism reflecting 
inflammation and immune activation in carcinogenesis prior to clinical lung cancer 
diagnosis. In other words, PAr may be a pre-diagnostic marker of lung cancer rather 




The association between PAr and lung cancer risk among current smokers was 
attenuated after careful adjustment for smoking duration and intensity. This suggests 
that PAr may be related to inflammation and immune activation induced by smoking, 
which is one of the mechanisms through which smoking causes lung cancer [22]. 
More importantly, the strong association among former smokers remained essentially 
unchanged after such adjustment, indicating that inflammation and immune activation 
affecting lung cancer risk measured by PAr is beyond history of tobacco exposure. 
Current smokers had low levels of PLP in our study [8], and low circulating PLP may 
increase to levels observed in never smokers after smoking cessation [10], which is 
confirmed by our study. Nevertheless, the PAr among former smokers was even 




circulating PA and PLP. Therefore, focusing on increased vitamin B6 catabolism 
provides new insight into lung carcinogenesis beyond PLP. 
 
Strengths and limitations 
 
This study has several strengths. First, the large sample size of 5,323 case-control 
pairs enabled well-powered subgroup analyses, and the inclusion of 20 prospective 
cohorts across 4 continents provided an unprecedented opportunity to evaluate the 
generalizability of the relation between PAr and lung cancer. Secondly, the centralized 
biochemical measurements with robust quality control further allowed for 
comparisons between individual cohorts and geographical regions. It has been shown 
that the components of the PAr (PA and PLP + pyridoxal) are stable during long term 
storage at -80°C [23]. Lastly, we also controlled for current tobacco exposure using 
cotinine measurements, and the intentional oversampling of never and former 
smokers allowed for well-powered stratified analysis by smoking status. However, 
this study also has limitations. Some cohorts restricted the recruitment to certain 
subject categories, in particular, several cohorts recruitment was limited to a specific 
sex, thus complicating between-cohort comparisons. In addition, information on 
histological data was missing for 34% of the lung cancer cases, thus our finding 
regarding histological types should be interpreted with caution. As in all 
epidemiological studies based on measurements at a single time point, our estimates 
may have underestimated the real association between PAr and lung cancer due to 







In conclusion, in this large analysis of 10,646 participants from 20 nested case-control 
studies, elevated PAr reflecting increased vitamin B6 catabolism was associated with 
an increased risk of lung cancer. This study robustly and comprehensively 
corroborates previous findings indicating that inflammation and immune activation as 
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Figure legend  
 
Figure 1. Multivariable-adjusted geometric means of PAr in 20 cohorts. Error bars 
indicate 95% CIs. Geometric mean (95% CI) of PAr in each cohort was estimated by 
using generalized linear model adjusted for age, sex and smoking (never, former and 
current smokers) and eGFR (continuous). 
Cohort abbreviations: ATBC, The Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention Study; CLUE, The Campaign Against Cancer and Stroke (CLUE I) and 
the Campaign Against Cancer and Heart Disease (CLUE II); CPS-II, The American 
Cancer Society Cancer Prevention Study-II Nutrition Cohort; HPFS, Health 
Professionals Follow-up Study; HUNT, The Nord-Trøndelag Health Study; MCCS, 
The Melbourne Collaborative Cohort Study; MDCS, The Malmö Diet and Cancer 
Study; MEC, The Multiethnic Cohort; NHS, The Nurses’ Health Study; NSHDS, The 
Northern Sweden Health and Disease Study Cohort; NYU, The New York University 
Women’s Health Study; PHS, Physicians’ Health Study; PLCO, Prostate, Lung, 
Colorectal and Ovarian  Cancer Screening Trial; SCCS, The Southern Community 
Cohort Study; SCHS, The Singapore Chinese Health Study; SCS, The Shanghai 
Cohort Study; SMHS, The Shanghai Men’s Health Study; SWHS, The Shanghai 
Women’s Health Study; WHI, The Women’s Health Initiative; WHS, Women’s Health 
Study. 
 
Figure 2. Pooled ORs (95% CIs) for lung cancer risk across PAr quartiles. The first 
quartile of PAr was used as the reference. OR for each quartile was pooled using a 
random-effects model based on 20 cohorts. Cohort-specific estimates were calculated 




concentrations as quartiles defined from the distribution among current smokers. 
 
Figure 3. Forest plot showing ORs (95% CIs) for lung cancer risk comparing the 
fourth to the first quartile of PAr. Cohort-specific ORs were calculated using 
conditional logistic regression adjusted for eGFR (continuous) and cotinine 
concentrations as quartiles defined from the distribution among current smokers. 
Results were combined using random effect models overall and for each region. 
 
Figure 4. Forest plot showing ORs (95% CIs) for lung cancer risk comparing the 
fourth to the first quartile of PAr, stratified by sex. Cohort-specific ORs were 
calculated using conditional logistic regression adjusted for eGFR (continuous) and 
cotinine concentrations as quartiles defined from the distribution among current 
smokers. Results were combined using random effect models for each region among 
men and women.  
 
